Zydus Lifesciences Ltd.
ZYDUSLIFE
Zydus Lifesciences Ltd. Share Price
1,099.20 -9.00 (-0.81%)Zydus Lifesciences Limited is a global pharmaceutical company headquartered in Ahmedabad, India.
It is a leading player in the generics market and has been at the forefront of developing new and innovative pharmaceutical products.
It is a fully integrated company, with a presence in the research and development, manufacturing, marketing, and distribution of pharmaceutical products.
Business Segment
Zydus has three main business segments:
- Generics: includes a range of generic products, including oral formulations, injectable formulations, and topical formulations
- Specialty formulations: offers a range of specialty formulations that require specialized manufacturing, such as transdermal patches, controlled-release tablets, and sustained-release capsules
- Biologics: Biologics are complex products that are derived from living organisms. The pharma company develops a range of biologics, such as biosimilars and vaccines
- Product Portfolio: Cadabolic injection, Bilypsa tablets 4MG, Ampilox DS 500/500 MG, Fusys 150 MG Tablet 1, and ATEN 25 MG Tablet 14 among others
Geographical Presence
The company’s global business has a strong presence in the regulated markets of the US, Europe, and in the high-profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
Fundamentals
Market Cap₹1,11,491Cr | EPS₹50.09 |
Book Value/Share₹269.43 | P/E Ratio (TTM)22.12 |
Industry P/E (TTM)46.93 | P/B Ratio4.11 |
Long Term D/E0.46 | ROE19.73% |
Dividend Yield (TTM)0.10% |
Analysis
Overview
Key stock indicators that show how well a company is doing, making it easier to understand its true value and performance.
Strong Outperformer
Somewhat Undervalued
Excellent Quality
Low Price Fluctuation
Analysts are Very Bullish
Peer Comparison
Peer comparison lists companies from the same sector, scored and ranked based on Crisp Analysis. It helps understand how a company stands against its competitors.
Shareholding Pattern
Shareholding pattern shows how a company’s shares (ownership) are distributed among different shareholding entities like promoters, Foreign Institutional Investors (FIIs), Domestic Institutional Investors (DIIs), and retail investors, among others. Changes in the shareholding pattern can indicate the performance outlook of a stock.
FAQs on Zydus Lifesciences Ltd.
The share price of Zydus Lifesciences Ltd. is ₹1,099.20 on NSE as of 28/7/2026, 8:38:19 pm. Share prices may change frequently due to market movements.
The market capitalisation of Zydus Lifesciences Ltd. is ₹1,11,491Cr as of 28/7/2026, 8:38:19 pm
The current Price to Earnings (P/E) ratio of Zydus Lifesciences Ltd. is 22.13 as of 28/7/2026, 8:38:19 pm
The Price to Book (P/B) ratio of Zydus Lifesciences Ltd. stands at 4.11 as of 28/7/2026, 8:38:19 pm
Zydus Lifesciences Ltd. reported an ROE of 19.74% for the last reported financial year on a consolidated account basis.
As of 28/7/2026, 8:38:19 pm, Zydus Lifesciences Ltd.’s shareholding pattern is: promoters hold 75.00%, FIIs hold 6.90%, DIIs hold 6.20%, and public shareholders hold 6.80%.
The 52-week high of Zydus Lifesciences Ltd. is ₹1,115.90 and the 52-week low is ₹1,095.20 as of 28/7/2026, 8:38:19 pm.
The earnings per share (EPS) of Zydus Lifesciences Ltd. is ₹12.65 for the quarter ended Mar 2026.
The stock symbol of Zydus Lifesciences Ltd. is ZYDUSLIFE.
You can buy Zydus Lifesciences Ltd. shares by opening a demat and trading account with Share.Market and placing a buy order on NSE or BSE during market hours.
The fair value of Zydus Lifesciences Ltd. depends on factors such as earnings growth, financial performance, and overall market conditions. Investors should assess fundamentals before making investment decisions.
Earnings Per Share
Earnings per share (EPS) measures the profit earned by a company for each of its outstanding shares. Generally, the higher a company’s EPS is, the more profitable it is considered to be.
Income Statement
Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.
| Particulars (in Cr) | Mar 2026 | Q/Q Change |
|---|---|---|
| Operating Revenue | 7,587.00 | +10.53% |
| Other Income | 134.20 | +20.47% |
| Total Income | 7,721.20 | +10.68% |
| Total Expenditure | 5,032.60 | -0.31% |
| EBIDT | 2,291.10 | +24.32% |
| Depreciation | 508.40 | +41.38% |
| Interest | 123.00 | -5.31% |
| Tax | 318.40 | -18.00% |
| Net Profit | 1,272.50 | +22.11% |
Balance Sheet
A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Total Current Assets | 19,906.10 |
| Total Non-Current Assets | 32,500.50 |
| Fixed assets | 20,261.60 |
| Total Assets | 52,406.60 |
| Total Current liabilities | 15,711.90 |
| Total Non Current Liabilities | 7,112.50 |
| Total Equity Plus Liabilities | 52,406.60 |
| Total Shareholder Funds | 27,111.40 |
| Total Debt to Equity | 43.00% |
Cash Flow
Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Cash from Operating Activity | 2,116.60 |
| Cash from Financing Activities | 5,806.90 |
| Cash from Investing Activities | -8,296.10 |
| Net Cash Flow | -372.60 |
Time Period: Daily
SMA/EMA (Moving Average) Analysis
Bullish Moving Averages7
Bearish Moving Averages9
5 Day
1,120.0010 Day
1,133.7020 Day
1,134.5030 Day
1,119.4050 Day
1,099.20100 Day
1,005.80150 Day
971.50200 Day
968.50Indicators
RSI (14)
46.01MACD (12, 26)
7.77MACD Signal Line (9)
15.70MFI (14)
48.38ATR (14)
24.51ADX (14)
32.07ROC (21)
0.62ROC (125)
26.47Pivot Analysis
Pivot analysis uses a special price point, called the pivot point, to show the overall market trend during different periods. This pivot point is the average of the previous day’s high, low, and closing prices of a specific asset.
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 1,121.47 | 1,134.73 | 1,143.27 | 1,112.93 | 1,099.67 | 1,091.13 | 1,077.87 |
Note: Support and Resistance level for the day, calculated based on price range of the previous trading day.
Volume Analysis
Volume analysis tracks how many shares were traded for a specific period. Total traded volume represents the overall number of shares traded, while combined delivery volume indicates only those shares which are delivered (transferred for ownership). Delivered shares indicate long-term investor interest.
Zydus Lifesciences Ltd.
ZYDUSLIFE
Open Price | 1,108.20 |
Prev Close | 1,108.20 |
Upper Circuit | 1,219.00 |
Lower Circuit | 997.40 |
Volume | 7,48,145 |
Average Traded Price | 1,104.14 |
Historical Performance
| 1 Day | NA |
| 5 Days | NA |
| 1 Month | NA |
| 3 Months | NA |
| 1 Year | NA |
| 5 Years | NA |
| 10 Years | NA |